Posterior cingulate atrophy and metabolic decline in early stage Alzheimer's disease

Neurobiol Aging. 2012 Sep;33(9):2006-17. doi: 10.1016/j.neurobiolaging.2011.07.009. Epub 2011 Aug 19.

Abstract

To test the hypothesis that Alzheimer's disease (AD) patients with posterior cingulate/precuneus (PCP) atrophy would be a distinct disease form in view of metabolic decline. Eighty-one AD patients underwent (18)F-fluorodeoxyglucose (FDG) positron emission tomography (PET) and structural magnetic resonance imaging (MRI). Positron emission tomography and voxel-based morphometry (VBM) Z-score maps were generated for the individual patients using age-specific normal databases. The patients were classified into 3 groups based on atrophic patterns (no-Hipp-PCP, atrophy in neither hippocampus nor PCP; Hipp, hippocampal atrophy; PCP, PCP atrophy). There were 16 patients classified as no-Hipp-PCP, 55 as Hipp, and 10 as PCP. The Mini Mental State Examination (MMSE) score was similar among the groups. The greater FDG decline than atrophy was observed in all groups, including the no-Hipp-PCP. The PCP group was younger, and was associated with a greater degree of FDG decline in PCP than the others. There are diverse atrophic patterns in a spectrum of AD. In particular, a subset of patients show PCP atrophy, which is associated with greater metabolic burden.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Alzheimer Disease / complications*
  • Alzheimer Disease / diagnostic imaging
  • Alzheimer Disease / metabolism
  • Alzheimer Disease / pathology*
  • Amyloid beta-Peptides / blood
  • Amyloid beta-Peptides / cerebrospinal fluid
  • Apolipoproteins E / genetics
  • Atrophy / diagnostic imaging
  • Atrophy / etiology
  • Atrophy / pathology
  • Attention
  • Brain Mapping*
  • Cognition
  • Female
  • Fluorodeoxyglucose F18
  • Gyrus Cinguli / diagnostic imaging
  • Gyrus Cinguli / pathology*
  • Humans
  • Learning
  • Magnetic Resonance Imaging
  • Male
  • Mental Status Schedule
  • Metabolic Diseases / diagnostic imaging
  • Metabolic Diseases / etiology*
  • Middle Aged
  • Neuropsychological Tests
  • Peptide Fragments / blood
  • Peptide Fragments / cerebrospinal fluid
  • Positron-Emission Tomography

Substances

  • Amyloid beta-Peptides
  • Apolipoproteins E
  • Peptide Fragments
  • amyloid beta-protein (1-42)
  • Fluorodeoxyglucose F18